期刊文献+

高血压用药的复方制剂 被引量:5

Drug usage of compound preparation for hypertension
下载PDF
导出
摘要 目的探讨高血压用药复方制剂的研究、临床应用状况及其发展趋势。方法采用内容分析方法,对高血压用药中复方制剂的组方原则、分类及其发展趋势进行分析总结,并在此基础上对其研究前景进行展望。结果高血压用药的复方制剂具有增强疗效、减少不良反应、有效抵御并发症等诸多优势,已成为治疗高血压的新方法。新的复方制剂组成概念关注高血压的综合治疗,小剂量固定剂量的复方制剂已经成为高血压药物治疗的新趋势。结论复方制剂将在高血压防治中发挥越来越重要的作用,并将在新药的开发和研究中占据重要的地位。 Objective To invest the research and clinical application of the cardiovascular and cerebrovascular medicine compound preparation, and its development trend. Methods With the content analysis methods, to summarize the principles, classifications and its development trends of the cardio-cerebral-vascular drugs in the compound preparation, and on this basis to prospect its research in the future. Results The cardiovascular and cerebrovascular drug compound formulation has many advantages, it can enhance the efficacy and reduce the adverse reactions, effectively against the complications and so on, it has become the new method to treat the cardiovascular and cerebrovascular diseaseses. The new conception of the compound preparations concern about the comprehensive treatment of the cardiovascular and cerebrovascular diseases, the small and fixed-doses of the compound preparation has become the new trend to treat the disease of high blood pressure. Conclusion The compound preparation will play a more and more importment role to prevent the heart and cerebrovascular diseases, and it will be in an important position at the development and research of new drugs.
作者 杨珂 王博
机构地区 河南大学
出处 《临床合理用药杂志》 2009年第9期31-33,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 高血压 复方制剂 用药 Hypertension Compound preparation Drug usage
  • 相关文献

参考文献10

二级参考文献16

  • 1柯元南.高血压的联合治疗[J].中国医师进修杂志(内科版),2006,29(1):3-6. 被引量:19
  • 2Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2003,42:239-246.
  • 3Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,29;356:366-372.
  • 4Howe P, Phillips P, Saini R, et al.The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999,21:1373-1396.
  • 5中国高血压防治指南起草委员会.1999中国高血压防治指南[J].高血压杂志,2000,8:94-112.
  • 6European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens,2003,21:1011-1053.
  • 7Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998,351:1755-1762.
  • 8孙宁玲.原发性高血压.见:王海燕主编.内科学[M].北京:.北京大学医学出版社,2005.316.
  • 9Biswas PN.The safety of valsartan:results of a postmarketing surveillance study on 12881 patients in England[J].J Hum Hypertens,2002,16(11):795-803.
  • 10Chrysant SG.Fixed combination therapy of hypertension:focus on valsartan/hydrochlorothiazide combination(Diovan/HCT)[J].Expert Rev Cardiovasc Ther,2003,1(3):335-343.

共引文献149

同被引文献33

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部